MCID: INS022
MIFTS: 39

in Situ Pulmonary Adenocarcinoma

Categories: Cancer diseases, Respiratory diseases

Aliases & Classifications for in Situ Pulmonary Adenocarcinoma

MalaCards integrated aliases for in Situ Pulmonary Adenocarcinoma:

Name: in Situ Pulmonary Adenocarcinoma 12 15
Bronchioloalveolar Adenocarcinoma 74
Bronchioalveolar Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0050870
UMLS 74 C0007120

Summaries for in Situ Pulmonary Adenocarcinoma

Disease Ontology : 12 A lung cancer that derives from the distal bronchioles or alveoli that initially exhibit a specific non-invasive growth pattern.

MalaCards based summary : in Situ Pulmonary Adenocarcinoma, also known as bronchioloalveolar adenocarcinoma, is related to retroperitoneal leiomyosarcoma and pulmonary artery leiomyosarcoma, and has symptoms including fever, dyspnea and hemoptysis. An important gene associated with in Situ Pulmonary Adenocarcinoma is LINC02288 (Long Intergenic Non-Protein Coding RNA 2288), and among its related pathways/superpathways are Glioma and Pathways in cancer. The drugs Gefitinib and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include lung, brain and heart, and related phenotypes are homeostasis/metabolism and mortality/aging

Related Diseases for in Situ Pulmonary Adenocarcinoma

Diseases related to in Situ Pulmonary Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 29)
# Related Disease Score Top Affiliating Genes
1 retroperitoneal leiomyosarcoma 10.2 PROM1 SMUG1
2 pulmonary artery leiomyosarcoma 10.2 CD68 SMUG1
3 sternum cancer 10.2 CD68 SMUG1
4 brain sarcoma 10.2 CD68 SMUG1
5 hepatic tuberculosis 10.1 SERPINA1 SMUG1
6 gastrointestinal system cancer 10.1 EGFR PROM1 SMUG1
7 female reproductive system disease 10.1 EGFR ESR2 SMUG1
8 reproductive system disease 10.1 EGFR ESR2 SMUG1
9 phacolytic glaucoma 10.1 CD68 SERPINA1
10 parasitic ichthyosporea infectious disease 10.1 CD68 SERPINA1
11 rhinosporidiosis 10.1 CD68 SERPINA1
12 inflammatory mfh 10.1 CD68 SERPINA1
13 lactocele 10.0 CD68 SMUG1
14 gastrointestinal system disease 10.0 EGFR SERPINA1 SMUG1
15 rhinoscleroma 10.0 CD68 SERPINA1
16 granulomatous myositis 10.0 CD68 SMUG1
17 nodular tenosynovitis 10.0 CD68 S100A9
18 hodgkin's lymphoma, lymphocytic depletion 10.0 ALK CD68
19 diffuse meningeal melanocytosis 9.9 CD68 S100A9
20 large intestine cancer 9.9 EGFR ESR2 PROM1 SMUG1
21 lung papillary adenocarcinoma 9.9 ALK EML4
22 pancreas adenocarcinoma 9.9 EGFR PROM1 SMUG1
23 xanthogranulomatous cholecystitis 9.8 CD68 S100A9 SMUG1
24 adult xanthogranuloma 9.8 CD68 S100A9 SERPINA1
25 reticulohistiocytic granuloma 9.8 CD68 S100A9 SERPINA1
26 lung adenoid cystic carcinoma 9.7 ALK EML4
27 respiratory system cancer 9.6 ALK EGFR EML4 SMUG1
28 erythema elevatum diutinum 9.6 CD68 S100A9
29 respiratory system disease 9.2 ALK EGFR EML4 IL33 SERPINA1 SMUG1

Graphical network of the top 20 diseases related to in Situ Pulmonary Adenocarcinoma:



Diseases related to in Situ Pulmonary Adenocarcinoma

Symptoms & Phenotypes for in Situ Pulmonary Adenocarcinoma

UMLS symptoms related to in Situ Pulmonary Adenocarcinoma:


fever, dyspnea, hemoptysis, coughing

MGI Mouse Phenotypes related to in Situ Pulmonary Adenocarcinoma:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.07 ALK ASPH EGFR ESR2 FGF19 HYAL2
2 mortality/aging MP:0010768 10 ALK ASPH EGFR ESR2 FGF19 HYAL2
3 neoplasm MP:0002006 9.5 ALK ASPH EGFR ESR2 ITGB1 PROM1
4 no phenotypic analysis MP:0003012 9.17 CD68 EGFR ESR2 HYAL2 IL33 PROM1

Drugs & Therapeutics for in Situ Pulmonary Adenocarcinoma

Drugs for in Situ Pulmonary Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 96)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gefitinib Approved, Investigational Phase 3,Phase 2,Phase 1 184475-35-2 123631
2
Paclitaxel Approved, Vet_approved Phase 2, Phase 3,Phase 3,Phase 1 33069-62-4 36314
3
Carboplatin Approved Phase 2, Phase 3,Phase 3,Phase 1 41575-94-4 38904 10339178 498142
4
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 441203 84093 2767
5
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
6
Bevacizumab Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 216974-75-3
7
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
8
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124
9
Lenograstim Approved, Investigational Phase 3,Phase 2 135968-09-1
10
Pemetrexed Approved, Investigational Phase 3,Phase 2,Phase 1 150399-23-8, 137281-23-3 60843 446556
11
leucovorin Approved Phase 3,Phase 2,Phase 1 58-05-9 6006 143
12
Vinorelbine Approved, Investigational Phase 3,Phase 2,Phase 1 71486-22-1 60780 44424639
13
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
14
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
15 Protein Kinase Inhibitors Phase 3,Phase 2,Phase 1
16
Erlotinib Hydrochloride Phase 3,Phase 2,Phase 1 183319-69-9 176871
17 Immunologic Factors Phase 2, Phase 3,Phase 3,Phase 1
18 Albumin-Bound Paclitaxel Phase 2, Phase 3,Phase 3,Phase 1
19 Antimitotic Agents Phase 2, Phase 3,Phase 3,Phase 1
20 Antineoplastic Agents, Phytogenic Phase 2, Phase 3,Phase 3,Phase 1
21 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
22 Antimetabolites Phase 3,Phase 2,Phase 1
23 Anti-Infective Agents Phase 3,Phase 2,Phase 1
24 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
25 Antiviral Agents Phase 3,Phase 2,Phase 1
26 Angiogenesis Modulating Agents Phase 2, Phase 3,Phase 3,Phase 1
27 Immunoglobulins Phase 2, Phase 3,Phase 1
28 Angiogenesis Inhibitors Phase 2, Phase 3,Phase 3,Phase 1
29 Antibodies, Monoclonal Phase 2, Phase 3,Phase 1
30 Antineoplastic Agents, Immunological Phase 2, Phase 3,Phase 3,Phase 1
31 Antibodies Phase 2, Phase 3,Phase 1
32 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
33 Etoposide phosphate Phase 3,Phase 2,Phase 1
34 Mitogens Phase 3,Phase 2
35 Vitamin B Complex Phase 3,Phase 2,Phase 1
36 Folic Acid Antagonists Phase 3,Phase 2,Phase 1
37 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1
38 Folate Phase 3,Phase 2,Phase 1
39 Vitamin B9 Phase 3,Phase 2,Phase 1
40 Hematinics Phase 3,Phase 2
41 Epoetin alfa Phase 3 113427-24-0
42 Anti-Bacterial Agents Phase 3,Phase 1,Phase 2
43
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
44
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
45
Diphenhydramine Approved, Investigational Phase 2 147-24-0, 58-73-1 3100
46
Promethazine Approved, Investigational Phase 2 60-87-7 4927
47
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
48
nivolumab Approved Phase 2 946414-94-4
49
Ipilimumab Approved Phase 2 477202-00-9
50
Metformin Approved Phase 2 657-24-9 14219 4091

Interventional clinical trials:

(show top 50) (show all 102)
# Name Status NCT ID Phase Drugs
1 Radiation Therapy to the Brain or Observation in Preventing Brain Metastases in Patients With Advanced Non-Small Cell Lung Cancer Unknown status NCT00955695 Phase 3 erlotinib hydrochloride;gefitinib
2 Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer Completed NCT00021060 Phase 2, Phase 3 paclitaxel;carboplatin
3 Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery Completed NCT00020709 Phase 3 cisplatin;docetaxel;etoposide;gefitinib
4 Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer Completed NCT00002852 Phase 3 paclitaxel;carboplatin
5 Cisplatin and Docetaxel With or Without Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Newly Diagnosed Stage III Non-Small Cell Lung Cancer Terminated NCT00113386 Phase 3 cisplatin;docetaxel
6 Chemotherapy Plus Radiation Therapy With or Without Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer Completed NCT00002550 Phase 3 cisplatin;etoposide
7 Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery Completed NCT00049543 Phase 3 gefitinib
8 Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Active, not recruiting NCT01107626 Phase 3 pemetrexed disodium
9 Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer Active, not recruiting NCT00499330 Phase 3
10 Chemotherapy and Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer Completed NCT00028938 Phase 3 carboplatin;paclitaxel
11 Chemotherapy Followed by Surgery or Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer Completed NCT00002623 Phase 3 carboplatin;cisplatin
12 Pazopanib Hydrochloride or a Placebo in Treating Patients With Non-Small Cell Lung Cancer Who Have Received First-Line Chemotherapy Terminated NCT01208064 Phase 2, Phase 3 pazopanib hydrochloride
13 Combination Chemotherapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer Withdrawn NCT00054392 Phase 3 carboplatin;gemcitabine hydrochloride;paclitaxel
14 Chemotherapy or Observation in Treating Patients With Early Stage Non-Small Cell Lung Cancer Terminated NCT00863512 Phase 3 cisplatin;docetaxel;gemcitabine hydrochloride;pemetrexed disodium;vinorelbine tartrate
15 Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer Terminated NCT00004859 Phase 3 carboplatin;paclitaxel;thalidomide
16 Gefitinib in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer Unknown status NCT00616499 Phase 2 gefitinib
17 Paclitaxel, Carboplatin, and Gefitinib in Treating Patients With Advanced Non-Small Cell Lung Cancer Unknown status NCT01024712 Phase 2 carboplatin;gefitinib;paclitaxel
18 Gemcitabine and Cisplatin Before or After Surgery in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer Unknown status NCT00398385 Phase 2 cisplatin;gemcitabine hydrochloride
19 VELCADE in Previously Treated Patients With Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma With BAC Features Terminated NCT00117351 Phase 2 VELCADE
20 S0635: Erlotinib and Bevacizumab in Stage IIIB and IV Bronchioloalveolar Carcinoma Active, not recruiting NCT00436332 Phase 2 erlotinib hydrochloride
21 Phase II Trial of Sunitinib in BAC or Never-Smokers With Any Lung Adenocarcinoma Completed NCT00430261 Phase 2 sunitinib
22 Gefitinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Completed NCT00029003 Phase 2 gefitinib
23 S0526: Pemetrexed Disodium in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Terminated NCT00265785 Phase 2 pemetrexed
24 S0310: Vaccine Therapy in Treating Patients With Stage IIIB or Stage IV Bronchoalveolar Lung Cancer Terminated NCT00074295 Phase 2
25 Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer Completed NCT00118144 Phase 2 bortezomib
26 Cetuximab in Treating Patients With Recurrent or Stage IIIB or Stage IV Lung Cancer Completed NCT00103207 Phase 2
27 Therapeutic Strategy in Advanced Bronchioloalveolar Carcinoma Completed NCT00384826 Phase 2 erlotinib;paclitaxel + carboplatine
28 Paclitaxel in Treating Patients With Lung Cancer Completed NCT00002972 Phase 2 paclitaxel
29 S9714: Paclitaxel in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer Completed NCT00002969 Phase 2 paclitaxel
30 Antineoplaston Therapy in Treating Patients With Recurrent or Stage IV Lung Cancer Terminated NCT00003494 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
31 A Study Of Oral GW572016 In Advanced Or Metastatic Non-Small Cell Lung Cancer Terminated NCT00073008 Phase 2 GW572016 (lapatinib)
32 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
33 Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer Completed NCT00416650 Phase 2 erlotinib hydrochloride
34 Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer Terminated NCT00955305 Phase 2 Carboplatin;Paclitaxel
35 MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy Completed NCT01294306 Phase 2 Akt Inhibitor MK2206;Erlotinib Hydrochloride
36 Bevacizumab, Pemetrexed Disodium, and Cisplatin or Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer. A Multicenter Phase II Trial Including Biopsy at Progression (BIO-PRO Trial). Completed NCT01116219 Phase 2 bevacizumab, pemetrexed, cisplatin
37 Gefitinib in Treating Patients With Previously Untreated Stage IIIB or Stage IV Non-Small Cell Lung Cancer Completed NCT00411047 Phase 2 gefitinib
38 Vaccine Therapy in Treating Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer Completed NCT00103116 Phase 2
39 Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer Completed NCT00003666 Phase 2 6-hydroxymethylacylfulvene
40 Video-Assisted Surgery Followed by Radiation Therapy in Treating Patients With Stage I Non-small Cell Lung Cancer and Poor Heart and Lung Function Completed NCT00002624 Phase 2
41 Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer Active, not recruiting NCT02186847 Phase 2 Carboplatin;Metformin Hydrochloride;Paclitaxel
42 Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Completed NCT01557959 Phase 2 cisplatin;erlotinib hydrochloride;docetaxel
43 S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer Completed NCT00368992 Phase 2 paclitaxel
44 Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery Active, not recruiting NCT01386385 Phase 1, Phase 2 Carboplatin;Paclitaxel;Veliparib
45 Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer Completed NCT00040794 Phase 2 paclitaxel;carboplatin;gefitinib
46 Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery Active, not recruiting NCT00334815 Phase 2 Cisplatin;Docetaxel;Etoposide
47 Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer Active, not recruiting NCT00126581 Phase 2 Carboplatin;Erlotinib Hydrochloride;Paclitaxel
48 Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer Active, not recruiting NCT00979212 Phase 2 panitumumab;carboplatin;paclitaxel
49 Carboplatin, Pemetrexed Disodium, and Bevacizumab for Patients With Stage III or IV Non-Small Cell Lung Cancer Who Are Light/Never Smokers Completed NCT01344824 Phase 2 carboplatin;erlotinib hydrochloride;pemetrexed disodium
50 Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Followed by Radiation Therapy and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery Completed NCT00553462 Phase 2 carboplatin;erlotinib hydrochloride;paclitaxel albumin-stabilized nanoparticle formulation

Search NIH Clinical Center for in Situ Pulmonary Adenocarcinoma

Genetic Tests for in Situ Pulmonary Adenocarcinoma

Anatomical Context for in Situ Pulmonary Adenocarcinoma

MalaCards organs/tissues related to in Situ Pulmonary Adenocarcinoma:

42
Lung, Brain, Heart, Testes, Endothelial, Smooth Muscle

Publications for in Situ Pulmonary Adenocarcinoma

Articles related to in Situ Pulmonary Adenocarcinoma:

# Title Authors Year
1
Bronchioloalveolar adenocarcinoma and pulmonary langerhans cell histiocytosis in a patient with MUTYH-associated polyposis. ( 21189386 )
2011
2
A single institution-based retrospective study of surgically treated bronchioloalveolar adenocarcinoma of the lung: clinicopathologic analysis, molecular features, and possible pitfalls in routine practice. ( 20521350 )
2010
3
Usefulness of Cdx2 in separating mucinous bronchioloalveolar adenocarcinoma of the lung from metastatic mucinous colorectal adenocarcinoma. ( 15362373 )
2004
4
Is high-grade adenomatous hyperplasia an early bronchioloalveolar adenocarcinoma? ( 14595748 )
2003
5
Early results of a prospective study of limited resection for bronchioloalveolar adenocarcinoma of the lung. ( 11269483 )
2001
6
Expression of alpha-smooth muscle actin in small bronchioloalveolar adenocarcinoma of the lung: assessment and comparison with noguchi criteria. ( 10523684 )
1999
7
Bronchioloalveolar adenocarcinoma of lung: monoclonal origin for multifocal disease. ( 9808126 )
1998
8
Bronchioloalveolar adenocarcinoma with myoepithelial cells. ( 1849448 )
1991

Variations for in Situ Pulmonary Adenocarcinoma

Expression for in Situ Pulmonary Adenocarcinoma

Search GEO for disease gene expression data for in Situ Pulmonary Adenocarcinoma.

Pathways for in Situ Pulmonary Adenocarcinoma

Pathways related to in Situ Pulmonary Adenocarcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.15 ALK EGFR EML4 ESR2 FGF19
2 11.82 ALK EGFR EML4 ESR2 FGF19 ITGB1
3 11.38 ITGB1 MSI1 PROM1 SERPINA1
4 10.58 EGFR ITGB1

GO Terms for in Situ Pulmonary Adenocarcinoma

Biological processes related to in Situ Pulmonary Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 viral entry into host cell GO:0046718 9.13 EGFR HYAL2 ITGB1
2 positive regulation of inflammatory response GO:0050729 8.92 EGFR HYAL2 IL33 S100A9

Molecular functions related to in Situ Pulmonary Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 virus receptor activity GO:0001618 8.8 EGFR HYAL2 ITGB1

Sources for in Situ Pulmonary Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....